Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome

被引:53
|
作者
Baroutis, G [1 ]
Kaleyias, J [1 ]
Liarou, T [1 ]
Papathoma, E [1 ]
Hatzistamatiou, Z [1 ]
Costalos, C [1 ]
机构
[1] Gen Dist Hosp Alexandra, Dept Neonatal Med, Athens, Greece
关键词
surfactant; respiratory distress syndrome; Alveofact; Poractant; Beractant;
D O I
10.1007/s00431-002-1144-0
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The aim of the study was to compare the treatment regimen of three natural surfactants of different extraction and formulation (Alveofact [Surfactant A = SA], Poractant [Surfactant B = SB] and Beractant [Surfactant C = SC]) in neonatal respiratory distress syndrome (RDS). Premature infants of less than or equal to32 weeks' gestation with birth weight of less than or equal to2,000 g and with established RDS requiring artificial ventilation with a FiO2 greater than or equal to0.3 were randomly assigned to receive at least two doses of SA, SB or SC (100 mg/kg per dose). Infants who remained dependent on artificial ventilation with a FiO2 greater than or equal to0.3 received up to two additional doses. There were no differences among the groups regarding the necessity for more than two doses. The SA and the SB groups spent fewer days on a ventilator (p-value SA/SB 0.7, SA/SC 0.05, SB/SC 0.043) compared with the SC group, needed fewer days of oxygen administration (p-value SA/SB 0.14, SA/SC 0.05, SB/SC 0.04) and spent fewer days in hospital (p-value SA/SB 0.65, SA/SC 0.04, SB/SC 0.027). There were no statistically significant differences in the incidence of mortality, chronic lung disease, air leaks, necrotising enterocolitis, retinopathy of prematurity and intraventricular haemorrhage among the three groups. Conclusion: the Alveofact and Poractant groups spent fewer days on the ventilator, needed fewer days of oxygen administration and spent fewer days in hospital compared with the Beractant group but no differences were observed among the three groups with regards to mortality and morbidity.
引用
收藏
页码:476 / 480
页数:5
相关论文
共 50 条
  • [31] Spectral characterization of neonatal arterial blood pressure associated with surfactant therapy for respiratory distress syndrome
    Talati, A
    Daley, ML
    Leffler, CW
    Bada, H
    PROCEEDINGS OF THE 19TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOL 19, PTS 1-6: MAGNIFICENT MILESTONES AND EMERGING OPPORTUNITIES IN MEDICAL ENGINEERING, 1997, 19 : 1124 - 1125
  • [32] SURFACTANT TREATMENT IN CHILDREN WITH ACQUIRED RESPIRATORY-DISTRESS SYNDROME
    MOLLER, JC
    REISS, I
    SCHAIBLE, T
    TEGTMEYER, FK
    GORTNER, L
    MONATSSCHRIFT KINDERHEILKUNDE, 1995, 143 (07) : 685 - 690
  • [33] Surfactant Replacement Therapy for the Prevention of the Neonatal Respiratory Distress Syndrome in Preterm Infants
    ZHOU XiaoGuang LUO XianQiong YANG LinLin CHEN YunBin ZHANG XiaoZhuang ZHAO QingGuoDepartment of Neonatology Maternal and Child Health Hospital of Guangdong Province Guangzhou China
    中国当代儿科杂志, 2001, (04) : 482 - 486
  • [34] History of Pulmonary Surfactant Replacement Therapy for Neonatal Respiratory Distress Syndrome in Korea
    Bae, Chong-Woo
    Kim, Chae Young
    Chung, Sung-Hoon
    Choi, Yong-Sung
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2019, 34 (25)
  • [35] Neonatal Respiratory Distress Syndrome: An Inflammatory Disease?
    Speer, Christian P.
    NEONATOLOGY, 2011, 99 (04) : 316 - 319
  • [36] The effect of varasurf surfactant on respiratory distress syndrome in rats
    Behrouz, Sepide
    Beigoli, Sima
    Ghalibaf, Mohammad Hossein Eshaghi
    Ghasemi, Seyedeh Zahra
    Boskabady, Mostafa
    Roshan, Nema Mohammadian
    Boskabady, Mohammad Hossein
    TOXICOLOGY AND ENVIRONMENTAL HEALTH SCIENCES, 2024, 16 (04) : 523 - 533
  • [37] A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome
    Hudak, ML
    Martin, DJ
    Egan, EA
    Matteson, EJ
    Cummings, J
    Jung, AL
    Kimberlin, LV
    Auten, RL
    Rosenberg, AA
    Asselin, JM
    Belcastro, MR
    Donohue, PK
    Hamm, CR
    Jansen, RD
    Brody, AS
    Riddlesberger, MM
    Montgomery, P
    PEDIATRICS, 1997, 100 (01) : 39 - 50
  • [38] Surfactant therapy using a bronchofiberscope in respiratory distress syndrome
    Wasa, Masanori
    Hasegawa, Hisaya
    Kihara, Hirotaka
    Yamada, Yosuke
    Mizogami, Masae
    Kitamura, Rei
    Ikeda, Kenta
    PEDIATRICS INTERNATIONAL, 2023, 65 (01)
  • [39] Current perspectives on the drug treatment of neonatal respiratory distress syndrome
    Sweet D.G.
    Pediatric Drugs, 1999, 1 (1) : 19 - 30
  • [40] Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome
    Lam, BCC
    Ng, YK
    Wong, KY
    PEDIATRIC PULMONOLOGY, 2005, 39 (01) : 64 - 69